The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? [electronic resource]
Producer: 20030710Description: 1673-80 p. digitalISSN:- 0250-7005
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biopsy
- Breast Neoplasms -- blood supply
- Cell Division -- drug effects
- Docetaxel
- Endothelial Growth Factors -- biosynthesis
- Female
- Humans
- Hypoxia-Inducible Factor 1, alpha Subunit
- Immunohistochemistry
- Intercellular Signaling Peptides and Proteins -- biosynthesis
- Lymphokines -- biosynthesis
- Neoplasm Recurrence, Local -- blood supply
- Neovascularization, Pathologic -- drug therapy
- Paclitaxel -- administration & dosage
- Prospective Studies
- Receptor, ErbB-2 -- biosynthesis
- Taxoids
- Transcription Factors -- metabolism
- Trastuzumab
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factors
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.